Por Dr. Marco Perin.
Left-Main Disease: When is PCI the Preferred Strategy?
Por Dr. Rafael Cavalcante.
Left Main Coronary Artery PCI Using State-of-the-Art Zotarolimus-Eluting Stents
Percutaneous coronary intervention (PCI) to the left main coronary artery (LMCA) with drug-eluting stent implantation is currently a major challenge due to the size of the vessel, the compromise of a bifurcation lesion in important branches, and the potential risk of complications. Available information on LMCA PCI comes from studies where DES stents were implanted<a href="https://solaci.org/en/2023/01/18/left-main-coronary-artery-pci-using-state-of-the-art-zotarolimus-eluting-stents/" title="Read more" >...</a>
Real-World Revascularization Strategy for Left Main Coronary Artery: Surgery or PCI?
There are many current randomized trials comparing percutaneous coronary intervention (PCI) with myocardial revascularization surgery (MRS) for the treatment of left main coronary artery disease (LMCAD). In the European Society of Cardiology guidelines, PCI is classified as Ia (LMCAD with low-complexity coronary disease) or IIa indication (intermediate complexity), whereas, according to the American Heart Association<a href="https://solaci.org/en/2023/01/11/real-world-revascularization-strategy-for-left-main-coronary-artery-surgery-or-pci/" title="Read more" >...</a>
Ticagrelor or Prasugrel Post-PCI in Daily Practice Patients
The ISAR-REACT 5 showed a significant reduction in the composite outcome of death, acute myocardial infarction (AMI), or stroke when using prasugrel vs. ticagrelor in patients with acute coronary syndrome (ACS), mainly at the expense of an AMI reduction. While this study changed clinical practice, it has stirred some criticism regarding certain methodological aspects, such<a href="https://solaci.org/en/2022/12/19/ticagrelor-or-prasugrel-post-pci-in-daily-practice-patients/" title="Read more" >...</a>
Post PCI FFR
Much research has been done on the usefulness of functional testing such as fractional Flow reserve (FFR) after percutaneous coronary intervention (PCI), resulting in the correlation of pathological FFR values with major adverse events at 6 months, as shown by Pijls, et al. The impact of post PCI FFR on prognosis has not been studied<a href="https://solaci.org/en/2022/11/30/post-pci-ffr/" title="Read more" >...</a>
Survey Stent-Save a Life! (SSL) / SOLACI | Procedural variation in the performance of Primary PCI
These last decades, primary percutaneous coronary intervention (PCI) has improved STEMI patient prognosis. However, its penetration varies across to regions and countries. As part of the initiative Stent-Save a Life! (SSL), SOLACI is publishing this electronic survey to assess the use of primary PCI throughout different countries based on the assumption that there is significant<a href="https://solaci.org/en/2022/10/19/survey-stent-save-a-life-ssl-solaci-procedural-variation-in-the-performance-of-primary-pci/" title="Read more" >...</a>
TCT 2022 | FAME-3 Trial: post PCI FFR And IVUS in Patients with Three-Vessel Disease
We are well aware of the benefits of Fractional Flow Reserve (FFR) to assess coronary artery stenosis. FFR after PCI (post-PCI FFR) has been shown to have prognostic value; however, few studies have included patients with complex three-vessel disease. The impact of intravascular ultrasound (IVUS) or optical computer tomography (OCT) in this field has been<a href="https://solaci.org/en/2022/09/22/tct-2022-fame-3-trial-post-pci-ffr-and-ivus-in-patients-with-three-vessel-disease/" title="Read more" >...</a>
Complex PCI: Distal Left Main Coronary Artery – SOLACI-SOCIME 2022
✔️ Complex PCI: Distal Left Main Coronary Artery – SOLACI-SOCIME 2022. ✔️ SOLACI-SOCIME 2022 Scientific Session. 👨‍🏫 Contents: 00:13 – Welcoming words – Dr. Álvaro Contreras (MEX) 01:18 – LM-PCI: IVUS and FFR/IFR? – Dr. Hector García-García (USA) 17:06 – DK Crush or provisional stenting? – Dr. Carlos Uribe (COL) 32:22 – Optimal antiplatelet anti<a href="https://solaci.org/en/2022/09/20/complex-pci-distal-left-main-coronary-artery-solaci-socime-2022-2/" title="Read more" >...</a>
PCI: New Paradigms – SOLACI-SOCIME 2022
✔️ PCI: New Paradigms – SOLACI-SOCIME 2022. ✔️ SOLACI-SOCIME 2022 Scientific Session. 👨‍🏫 Contents: 00:03 – Welcoming words – Dr. Jorge Cortés (MEX) 01:29 – PCI: Transitioning from treatment of ischemia to vulnerable plaque. Keynote Lecture – Dr. Gregg Stone (USA)41:33 – Comments and analysis of the master conference – Dr. Jorge Cortés (MEX) 45:35–<a href="https://solaci.org/en/2022/09/19/pci-new-paradigms-solaci-socime-2022-2/" title="Read more" >...</a>